SCHEMBL6484776

SCHEMBL6484776

Clc1cc(Nc2ncnc(Cl)n2)c2ccccc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 1/20 0.38
FADS1 O60427 2/20 0.38
LMNA P02545 1/20 0.38
ULK1 O75385 1/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
SLC6A2 P23975 1/20 0.35
PDE4A P27815 1/20 0.35
KDR P35968 1/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482620 0.83 ULK1 (0.49) SMN1; SMN2NPC1RAB9ATSHRFADS1
SCHEMBL6206101 0.74 TSHR (0.68) SMN1; SMN2NPC1RAB9ATSHRLMNA
SCHEMBL6489892 0.73 RAPGEF4 (0.49) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL13395050 0.72 AURKA (0.47) SMN1; SMN2NPC1RAB9ATSHRLMNA
SCHEMBL17366289 0.72 HTT (0.67) SMN1; SMN2NPC1RAB9ATSHRLMNA
SCHEMBL6545045 0.71 ULK1 (0.55) SMN1; SMN2NPC1RAB9ATSHRFADS1
SCHEMBL4795724 0.71 MAPT (0.66) NPC1RAB9ALMNAMAPTKMT2A
SCHEMBL10341607 0.70 HPGDS (0.46) SMN1; SMN2NPC1RAB9ATSHRLMNA
SCHEMBL4947229 0.69 SYK (0.56) FADS1MAPTKMT2AKDRALDH1A1
SCHEMBL27937956 0.69 FADS1 (0.43) TSHRFADS1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881737-B2 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. (US) 2005-04-19 US disclosed
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP disclosed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US disclosed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS SMN1; SMN2 4731/4885NPC1 2228/4885RAB9A 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.